Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT

Results expected for Q3, 2014 April 23, 2014 Anergis, a company discovering and developing proprietary allergy vaccines, today announced that it has completed the enrolment of 196 subjects in the long-term efficacy trial of its birch pollen allergy vaccine AllerT, and expects to release results in the third quarter of 2014. The long-term efficacy trial of AllerT is a double-blind, …